FOCUS: PHARMACEUTICAL
GLP-1 compound clash in court as Big Pharma pushes back
The High Court battle which started this week between pharmaceutical giant Novo Nordisk and a Pretoria pharmacy shone the spotlight on GLP-1 drugs and the frenzied market demand that has resulted in a compounding explosion, and also has implications for pharmacies facing pushback against compounded drugs worldwide.
Novo Nordisk – maker of Wegovy and Ozempic – took Pretoria pharmacy iDexis to court yesterday over its use of a patented compound, the outcome of which is likely to affect the fate...


